Innotox 50 Units

Description

Innotox 50 Units is an innovative, pre-diluted botulinum toxin type A complex developed by Medytox Inc. (South Korea) and distributed globally under various brand names. Unlike traditional lyophilized botulinum toxins that require reconstitution with saline, Innotox is supplied as a stable, liquid solution in a single-use vial containing 50 units of toxin already formulated with sodium chloride and no preservatives or complexing proteins in some presentations. This unique liquid form provides consistent concentration, eliminates reconstitution errors, reduces preparation time, and minimizes risk of contamination or dilution variability.

Innotox works by inhibiting acetylcholine release at the neuromuscular junction, producing targeted, temporary muscle relaxation or suppression of glandular secretion—widely regarded as a high-purity, effective alternative to other botulinum toxins with comparable or slightly faster onset and similar duration.

Aesthetic Uses

Innotox 50 Units is approved in many countries for the temporary improvement of moderate to severe:

• Glabellar frown lines
• Lateral canthal lines (crow’s feet)
• Horizontal forehead lines

The 50-unit vial is ideal for:

• Smaller treatment areas or subtle corrections
• Patients new to neuromodulators or preferring conservative dosing
• Precise treatments (periorbital lines, bunny lines, lip lines, chin dimpling)
• Off-label aesthetic indications including masseter reduction (jaw slimming), platysmal bands, gummy smile, perioral rhytids, or hyperhidrosis

Typical cosmetic doses range from 10–40 units per session, with onset often visible in 2–5 days (slightly faster than some competitors in user reports), peak effect at 7–14 days, and duration generally 3–6 months.

Therapeutic Uses

Innotox is approved or used off-label in various regions for:

• Blepharospasm
• Cervical dystonia
• Upper/lower limb spasticity
• Focal hyperhidrosis
• Hemifacial spasm

Therapeutic doses vary (often 50–200+ units total), requiring expert placement and frequently EMG guidance.

Administration & Handling

• No reconstitution needed — ready-to-use liquid format
• Stable refrigerated (2–8°C) until expiry; do not freeze
• Inject via fine-gauge needles (30–33G) or cannulas in aesthetic applications

Safety & Side Effects

Common side effects are mild and transient: injection-site pain, swelling, bruising, headache, eyelid ptosis, dry eyes, or mild flu-like symptoms. Serious but rare risks include distant spread of toxin effects (dysphagia, respiratory distress), allergic reactions, or antibody-mediated resistance with repeated use. Contraindications include hypersensitivity to botulinum toxin or excipients, active infection at injection site, and certain neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS).

As of 2026, Innotox 50 Units is approved in over 60 countries (including South Korea, Europe, Asia, Latin America, the Middle East, and others) and has gained strong global adoption due to its high purity, liquid convenience, consistent potency, and competitive pricing. It is not FDA-approved in the United States (where similar products include Botox, Dysport, Xeomin, and Jeuveau), but it is legally and widely used in many regions. Innotox must be administered only by qualified healthcare professionals (dermatologists, plastic surgeons, neurologists, etc.) trained in botulinum toxin injection techniques, with thorough patient assessment, informed consent, and follow-up. Always source genuine Innotox from authorized distributors to ensure authenticity, potency, and safety.